Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

Autor: Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, Tineke Casneuf, Nikki DeAngelis, Himal Amin, Jon Ukropec, Rachel Kobos, Maria-Victoria Mateos

Publikováno v: Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-11 (2020)

Abstract Background Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exh

Externí odkaz: https://doaj.org/article/f4bcd4b8584c4c2d8d002b323f628268

Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma

Autor: Anne‐Gaelle Dosne, Xia Li, Man Melody Luo, Ivo Nnane, Meletios A. Dimopoulos, Evangelos Terpos, Pieter Sonneveld, Tobias Kampfenkel, Robin Carson, Himal Amin, Juan Perez Ruixo, Honghui Zhou, Yu‐Nien Sun, Yan Xu

Publikováno v: British Journal of Clinical Pharmacology, 89(5), 1640-1655. Wiley-Blackwell Publishing Ltd

Aim: A population pharmacokinetic (PPK) model was developed to characterize pharmacokinetics (PK) of subcutaneous or intravenous daratumumab administration in a new indication (i.e., combination with pomalidomide and dexamethasone [D-Pd] in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46ab93224854f5820df05a5c20f87458
https://pubmed.ncbi.nlm.nih.gov/36484341

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

Autor: Xiang Qin, Paolo Corradini, Wolney Barreto, Rachel Kobos, Vania Hungria, Chang-Ki Min, Christopher Chiu, Jon Ukropec, Maria-Victoria Mateos, Pieter Sonneveld, Andrew Spencer, Eva Medvedova, Jordan M. Schecter, Himal Amin, Ajay K. Nooka, Katja Weisel, Jane Estell

Publikováno v: Clinical Lymphoma Myeloma & Leukemia, 20(8), 509-518. Cancer Media Group

In the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone. Outcomes after 40.0 months of median follow-up are discussed.Eligib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ade9739e28ddf4ed91b68ce4332d93d4
https://doi.org/10.1016/j.clml.2019.09.623

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Autor: Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, Robin Carson, Pieter Sonneveld, Adrian Alegre Amor, Angelo Belotti, Lotfi Benboubker, Britta Besemer, Sevgi Besisik, Michele Cavo, Javier De La Rubia Comos, Meletios A. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Facon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hajek, Guner Hayri Ozsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Stefan Knop, Marie-Christine Kyrtsonis, Juan Jose Lahuerta, Xavier Leleu, Carmen Martinez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique Minnema, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlivan, Ludek Pour, Henk Th.J. Roerdink, Laura Rosinol Dacsh, Hans Salwender, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tulin Tuglular, Ali Unal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
APOLLO Trial Investigators 2021, ' Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 6, pp. 801-812 . https://doi.org/10.1016/S1470-2045(21)00128-5
LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
The Lancet. Oncology, 22(6), 801-812. Lancet Publishing Group
The Lancet Oncology, 22(6), 801-812. Lancet Publishing Group

Background: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c27bb717191298826d5623e5b11470
http://hdl.handle.net/10261/261314

Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

Autor: Mario Boccadoro, Robin Carson, Jelena Bila, Namphuong Tran, Tobias Kampfenkel, Sosana Delimpasi, Evangelos Terpos, Ioannis Orfanidis, Himal Amin, Michele Kosh, Maria-Victoria Mateos, Philippe Moreau, Meral Beksac, Luca Baldini, Eirini Katodritou, Albert Oriol, Pieter Sonneveld, Yanping Qiu, Meletios A. Dimopoulos, Argiris Symeonidis, Hermann Einsele

Publikováno v: Blood. 138:2747-2747

Introduction: Daratumumab (DARA) is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action. DARA is approved as monotherapy or in combination with standard-of-care regimens for the treatment o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9af4d38db109cfd01f62060be6fb5b0a
https://doi.org/10.1182/blood-2021-146907